Iambic’s $150 Million IPO Puts AI Drugmaking to the Test
Iambic’s $150 million IPO brings its AI drugmaking business to public investors, with clinical evidence and spending priorities now central to the investment case.
The full article is being collected. Available text is shown for now.
Source: biotech-insider.com ↗